Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Medicine (Baltimore) ; 102(45): e36010, 2023 Nov 10.
Article in English | MEDLINE | ID: mdl-37960757

ABSTRACT

RATIONALE: Gefitinib is a potent and selective orally active growth factor receptor (EGFR)-tyrosine kinase inhibitor that is commonly used to treat advanced non-small cell lung cancer patients with activating EGFR mutations. Hearing impairment with gefitinib was sparsely reported. In this report, we describe a case of sensorineural deafness associated with the administration of gefitinib, with a Naranjo score of 7. PATIENT CONCERNS: An 81-year-old female was diagnosed with lung adenocarcinoma with bone metastasis and an EGFR-activating mutation. The patient was prescribed gefitinib tablets at a daily dose of 250 mg for lung adenocarcinoma treatment. However, the patient experienced moderate to severe bilateral sensorineural deafness, primarily in her right ear, after taking gefitinib. Following the cessation of gefitinib administration, the patient exhibited partial restoration of auditory function. Upon resuming the medication, she experienced a worsening of deafness. DIAGNOSES: The otoscopic audiogram and hearing test indicated moderate to severe bilateral sensorineural deafness. INTERVENTIONS: The otolaryngologist recommended bilateral hearing aids to enhance hearing function. OUTCOMES: Throughout our follow-up period, the patient did not receive a hearing aid implant. LESSONS: This article first reported the ototoxicity caused by gefitinib. While rare, our report highlights that gefitinib-induced sensorineural deafness is possible and its mechanisms are still unclear. This adverse reaction should be monitored closely during clinical application of gefitinib to improve patient outcomes.


Subject(s)
Adenocarcinoma of Lung , Carcinoma, Non-Small-Cell Lung , Deafness , Hearing Loss, Sensorineural , Lung Neoplasms , Humans , Female , Aged, 80 and over , Gefitinib/adverse effects , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/pathology , Hearing Loss, Sensorineural/chemically induced , ErbB Receptors/metabolism , Mutation
2.
Front Immunol ; 13: 967506, 2022.
Article in English | MEDLINE | ID: mdl-35967334

ABSTRACT

Background: Patients with systemic lupus erythematosus (SLE) are at increased risk of cardiovascular disease (CVD) compared to the general population. However, little is known about the effects of tobacco smoking on CVD in patients with SLE. Objective: To systematically review and summarize the available literature regarding the effects of tobacco smoking on developing CVD in patients with SLE. Methods: We retrieved relevant studies from the following databases: PubMed, EMBASE, Web of Science and China National Knowledge Internet (CNKI) database. Two reviewers independently reviewed the eligible studies, assessed their validity, and extracted relevant data. Sensitivity and subgroup analyses were performed to distinguish sources of heterogeneity. Results: A total of 10 studies, which comprised 6984 participants, were included in the analysis. The overall quality of evidence was rated as moderate to low. The smoking prevalence among CVD patients was 39.28% (271/690), which was higher than 31.36% (1974/6294) among non-CVD patients. Compared with never-smokers, the risk of developing CVD in current smokers was 1.42 (95% CI: 1.21-1.66). No significant publication bias was found in our meta-analysis. Conclusions: In spite of the several negative results, this study found that current smokers with SLE have an increased risk of developing CVD, although most of the included studies were in low-to-moderate quality. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022338109.


Subject(s)
Cardiovascular Diseases , Lupus Erythematosus, Systemic , Cardiovascular Diseases/complications , Cardiovascular Diseases/etiology , Humans , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/epidemiology , Prevalence , Smoking/adverse effects , Smoking/epidemiology , Tobacco Smoking/adverse effects , Tobacco Smoking/epidemiology
3.
Front Pharmacol ; 12: 771804, 2021.
Article in English | MEDLINE | ID: mdl-34858190

ABSTRACT

Background: Multiple studies have revealed that idiopathic pulmonary fibrosis (IPF) patients are more at risk for cardiovascular diseases and that many IPF patients receive cardiovascular medications like statins, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), and anticoagulants. Existing studies have reported divergent findings on the link between cardiovascular medications and fibrotic disease processes. The aim of this study is to synthesize the evidence on the efficacy of cardiovascular medications in IPF. Methods: We searched studies reporting the effect of cardiovascular medications on IPF in the PubMed, Embase, Web of Science, Cochrane Library, and two Chinese databases (China National Knowledge Infrastructure database and China Wanfang database). We calculated survival data, forced vital capacity (FVC) decline, and IPF-related mortality to assess the efficacy of cardiovascular medications in IPF. We also estimated statistical heterogeneity by using I2 and Cochran Q tests, and publication bias was evaluated by risk of bias tools ROBINS-I. Results: A total of 12 studies were included in the analysis. The included studies had moderate-to-serious risk of bias. Statin use was associated with a reduction in mortality (hazard ratio (HR), 0.89; 95% CI 0.83-0.97). Meta-analysis did not demonstrate any significant relationship between statin use and the FVC decline (HR, 0.86; 95% CI 0.73-1.02), ACEI/ARB use, and survival data (HR, 0.92; 95% CI 0.73-1.15) as well as anticoagulant use and survival data (HR, 1.16; 95% CI 0.62-2.19). Conclusion: Our study suggested that there is a consistent relationship between statin therapy and survival data in IPF population. However, there is currently insufficient evidence to conclude the effect of ACEI, ARB, and anticoagulant therapy on IPF population especially to the disease-related outcomes in IPF.

4.
Front Pharmacol ; 12: 730681, 2021.
Article in English | MEDLINE | ID: mdl-34475825

ABSTRACT

Background: Administration of aspirin has the potential for significant side effects of gastrointestinal (GI) injury mainly caused by gastric acid stimulation, especially in long-term users or users with original gastrointestinal diseases. The debate on the optimal treatment of aspirin-induced gastrointestinal injury is ongoing. We aimed to compare and rank the different treatments for aspirin-induced gastrointestinal injury based on current evidence. Methods: We searched PubMed, EMBASE, Cochrane Library (Cochrane Central Register of Controlled Trials), and Chinese databases for published randomized controlled trials (RCTs) of different treatments for aspirin-induced gastrointestinal injury from inception to 1 May 2021. All of the direct and indirect evidence included was rated by network meta-analysis under a Bayesian framework. Results: A total of 10 RCTs, which comprised 503 participants, were included in the analysis. The overall quality of evidence was rated as moderate to high. Eleven different treatments, including omeprazole, lansoprazole, rabeprazole, famotidine, geranylgeranylacetone, misoprostol, ranitidine bismuth citrate, chili, phosphatidylcholine complex, omeprazole plus rebamipide, and placebo, were evaluated in terms of preventing gastrointestinal injury. It was suggested that omeprazole plus rebamipide outperformed other treatments, whereas geranylgeranylacetone and placebo were among the least treatments. Conclusion: This is the first systematic review and network meta-analysis of different treatments for aspirin-induced gastrointestinal injury. Our study suggested that omeprazole plus rebamipide might be considered the best option to treat aspirin-induced gastrointestinal injury. More multicenter, high quality, large sample size randomized controlled trials will confirm the advantages of these medicines in the treatment of aspirin-induced gastrointestinal injury in the future.

5.
Article in English | MEDLINE | ID: mdl-34335822

ABSTRACT

BACKGROUND: Aspirin is the first-line medication for prevention and treatment of coronary heart disease (CHD). However, long-term use of aspirin resulting in gastrointestinal mucosal injury and bleeding limits the regularity of medication. Xuesaitong is a marketed Chinese medicine contained main active component in Panax notoginseng saponins (PNS), which can significantly inhibit platelet aggregation in patients with CHD. Our previous studies have already showed that PNS could reduce the gastrointestinal mucosal injury caused by aspirin in preclinical study. However, there is a need for further clinical studies to evaluate synergy and attenuation effect of the combination. METHODS: This trial is a prospectively planned, open-labeled, parallel-grouped, single-centered clinical trial. A total of eligible 480 participants will be randomly allocated into three groups: aspirin group, Xuesaitong group, and drug combination group at a ratio of 1 : 1 : 1. The primary outcome is the change of platelet aggregation rate and calprotectin activity. Secondary outcomes include PAC-1, P-selectin, P2Y12, I-FABP activity, and fecal occult blood. Discussion. The results of the study are expected to provide evidence of high methodological and reporting quality on the synergy function of Xuesaitong and aspirin upon the antiplatelet and anti-gastrointestinal injury effect for CHD. It also provides an experimental basis for clinical rational drug combination therapy. Trial Registration. This trial was registered in the Chinese Clinical Trail Registry, ChiCTR2000036311, on 22 August 2020, http://www.chictr.org.cn/edit.aspx?pid=58798&htm=4.

6.
Zhongguo Zhong Yao Za Zhi ; 41(20): 3761-3766, 2016 Oct.
Article in Chinese | MEDLINE | ID: mdl-28929653

ABSTRACT

To investigate the dynamic changes of endogenous hormones contents in Salvia miltiorrhiza after the inoculation of Glomus versiforme(GV).The contents of endogenous hormones of ABA, ZR, GA, IAA and MeJA by ELISA were measured. Infection rata of GV reached plateau of 90% at the 90th d of inoculation; fresh weight of overground part and leaf number were significantly higher in GV group, with 2.7 and 1.96 fold than that of control; contents of all endogenous hormones apart from ABA in over- and under-ground part were markedly lower (P<0.05) in GV group at the 75th and 90th d, respectively, with 63% to 75% and 45% to 81% of that in control, and were significantly higher (P<0.05) in both over- and under-ground part in GV group at the 105th d, with 1.4 to 1.7 fold higher than that of control; content of ABA in underground part increased significantly at 60th, 75th and 105th d. Arbuscular mycorrhizal fungi could promote the growth of S. miltiorrhiza, and affect the dynamic changes of endogenous hormones contents in different infection periods.


Subject(s)
Glomeromycota/physiology , Mycorrhizae/physiology , Plant Growth Regulators/analysis , Salvia miltiorrhiza/microbiology , Plant Leaves/chemistry , Plants, Medicinal/chemistry , Plants, Medicinal/growth & development , Plants, Medicinal/microbiology , Salvia miltiorrhiza/chemistry , Salvia miltiorrhiza/growth & development
7.
Zhong Yao Cai ; 37(6): 927-31, 2014 Jun.
Article in Chinese | MEDLINE | ID: mdl-25470952

ABSTRACT

OBJECTIVE: To investigate the effects of different types of elicitors on the secondary metabolism of Sorbus aucuparia cell). METHODS: Added three different types of elicitors [ yeast extract ( YE), heavy metal ions and allelochemicals] to the SACC, and deleted the changes in the secondary metabolism of SACC using GC-MS. RESULTS: Treatment of SACC with yeast extract in- tion of biphenyls, and some long-chain fatty acids and steroids disappeared; The addition of heavy metal ions induced the g-chain fatty acids, and some steroids and triterpenes disappeared; And the addition of allelochemicals led to the disappearance long-chain fatty acids, steroids and triterpenes. CONCLUSION: These three types of elicitors have different effects on the secondary metabolism of SACC, but different elicitors of the same type act almost the same, which implies different kinds of elicitors would activate different pathways of secondary metabolism in SACC.


Subject(s)
Secondary Metabolism/drug effects , Sorbus/metabolism , Biphenyl Compounds
8.
Guang Pu Xue Yu Guang Pu Fen Xi ; 33(5): 1211-4, 2013 May.
Article in Chinese | MEDLINE | ID: mdl-23905321

ABSTRACT

Portable near infrared spectrometer combined with multi-class support vector machines was used to discriminate wolfberry fruit of different geographic regions. Data pre-processing methods were explored before modeling with the identification rate as indicator. To eliminate the influence of sample subset partitioning on model performance, multiple modeling and predicting were conducted and the statistical result of identification rate was utilized to assess model performance of different acquisition sites. The results showed that SVM model with raw spectra after pretreatment of second derivative and Savitzky-Golay filter smoothing showed the best predicative ability. And the model of every acquisition site except for site 5 exhibited good stability and prediction ability and its median and average of identification rate of external validation were all greater than 97%. It was suggested that surface NIR spectra of wolfberry fruit was applicable to accurate identification of geographic region, and portable near infrared spectrometer could act as an effective means of monitoring the quality of Chinese herbal medicine in circulation.


Subject(s)
Lycium/chemistry , Lycium/classification , Spectroscopy, Near-Infrared/methods , Support Vector Machine
SELECTION OF CITATIONS
SEARCH DETAIL
...